NF 340: Transforming P2Y11 Antagonist Use in Cancer Research

Principle Overview: NF 340 as a P2Y11 Antagonist

NF 340 (sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate) is a potent and selective P2Y11 antagonist supplied by APExBIO (product_spec). By specifically targeting the P2Y11 receptor—a member of the purinergic GPCR family—NF 340 enables precise dissection of downstream signaling events critical in inflammation pathway modulation, immune response, and cancer metastasis. Its selectivity and robust inhibition profile distinguish it from less-specific cell signaling inhibitors, providing the foundation for reproducible, mechanistically clear research outcomes (source: article).

Step-by-Step Workflow: Protocol Enhancements with NF 340

Optimizing the use of NF 340 as a cell signaling inhibitor requires careful attention to solubility, timing, and downstream assay selection. Drawing from both product specifications and recent literature, the following workflow ensures maximal efficacy and data clarity.

Protocol Parameters

• Assay: In vitro cell migration/invasion (e.g., Transwell) | Value: 10 μM NF 340 | Applicability: Breast cancer cell lines (e.g., MDA-MB-231, BT-20) | Rationale: Effective reversal of QPRT-induced invasiveness as demonstrated in Liu et al. 2021 | Source: paper
• Incubation time: 18–24 hours | Applicability: Functional readouts (migration, invasion, signaling) | Rationale: Sufficient for observing changes in myosin light chain phosphorylation and cell motility | Source: paper
• Solution preparation: Dissolve up to 19.74 mg/ml in water (use immediately) | Applicability: All in vitro assays | Rationale: Ensures stability and potency, as NF 340 solutions are not recommended for long-term storage | Source: product_spec
• Storage: -20°C (solid) | Applicability: Stock material | Rationale: Maintains compound integrity; avoid repeated freeze-thaw cycles | Source: product_spec

Key Innovation from the Reference Study

The pivotal study by Liu et al. (2021) established that NF 340 can reverse breast cancer cell invasiveness driven by quinolinate phosphoribosyltransferase (QPRT) via inhibition of myosin light chain phosphorylation (paper). This finding directly links P2Y receptor signaling to cytoskeletal regulation in cancer cells, offering a previously underexplored axis for intervention. Practically, this supports the use of NF 340 at 10 μM in migration/invasion assays to probe purinergic mechanisms underpinning metastatic behavior. The study's workflow—combining QPRT overexpression/knockdown with antagonist treatment—serves as a blueprint for evaluating GPCR-driven phenotypes in diverse cell types.

Advanced Applications and Comparative Advantages

NF 340’s specificity as a G protein-coupled receptor antagonist enables researchers to untangle complex purinergic signaling networks implicated in immunology research, cancer progression, and inflammation pathway modulation. In the study by Liu et al., NF 340 provided clear mechanistic evidence that P2Y11 antagonism can block a key step in cancer cell invasion, outperforming less-selective inhibitors (paper). This aligns with findings from P2Y11 Antagonist B7508: Precision Tool for GPCR Signaling, which highlights the reagent’s unrivaled selectivity for dissecting receptor-specific pathways.

Moreover, NF 340’s utility extends to studies dissecting inflammation and immune modulation, as discussed in Strategic Disruption of Purinergic Signaling. There, the compound is positioned as a strategic enabler for translational research, providing reproducible inhibition across a spectrum of GPCR-mediated phenomena. Compared to traditional cell signaling inhibitors, NF 340 offers improved reproducibility and mechanistic clarity (source: article).

Troubleshooting and Optimization Tips

• Solubility: NF 340 exhibits limited solubility in water (≤19.74 mg/ml). To maximize dissolution, warm water to 37°C and vortex briefly. Prepare fresh solutions for each experiment to avoid degradation (source: product_spec).
• Compound Stability: Avoid storing prepared NF 340 solutions. If delays are unavoidable, keep solutions at 4°C for a maximum of several hours and discard unused portions (workflow_recommendation).
• Assay Interference: For assays sensitive to sodium or sulfonate moieties, include appropriate vehicle controls to discern compound effects from buffer-related artifacts (workflow_recommendation).
• Concentration Selection: Empirically validate 10 μM as a starting point for novel cell systems. Titrate in 2–3 fold increments (e.g., 5, 10, 20 μM) to establish optimal response while monitoring cell viability (source: paper).
• Readout Timing: For dynamic phenotypic assays (e.g., wound healing, migration), monitor cells at multiple intervals (6, 18, 24 hours) to capture early and late effects, especially when mapping signaling cascades (workflow_recommendation).

Interlinking Existing Resources: Building a Cohesive Research Strategy

The workflow described here complements the protocol enhancements and troubleshooting expertise detailed in P2Y11 Antagonist (B7508): Reliable Inhibition for Cell Signaling, which offers actionable, scenario-based guidance for optimizing reproducibility. Meanwhile, P2Y11 Antagonist: Precision Inhibition of GPCR Signaling extends these insights with comparative data on reproducibility and data clarity, reinforcing the strategic value of APExBIO’s NF 340 for advanced cell signaling studies. Together, these resources form a robust foundation for researchers seeking to accelerate translational breakthroughs in GPCR pathway research.

Future Outlook: Implications for Translational Research

The integration of NF 340 into experimental workflows marks a significant leap in the study of P2Y receptor signaling, particularly in the context of cancer metastasis and immune modulation. The findings of Liu et al. (2021) suggest that targeting the P2Y11 axis may have profound implications for limiting cancer invasiveness and offer a mechanistic foothold for future therapeutic development (paper). As more researchers adopt highly selective antagonists like NF 340, the field can expect enhanced reproducibility, deeper mechanistic insights, and more rapid translation of bench findings to preclinical models.

However, it remains essential to rigorously validate findings across diverse cell systems and pathological contexts. While NF 340 has emerged as a gold standard for P2Y11 inhibition in vitro, further studies are needed to fully map its impact in complex tissue environments and in vivo models (workflow_recommendation).

For those seeking a reliable, evidence-backed P2Y11 antagonist, NF 340 from APExBIO stands at the forefront, providing the specificity and performance required for next-generation GPCR and cancer research.